Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.1 USD -7.56% Intraday chart for FibroGen, Inc. -8.33% +24.11%
Jun. 04 Top Premarket Gainers MT
Jun. 03 FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Premarket Gainers
MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK
DJ
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
AQ
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
AQ
FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
CI
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting
CI
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
AQ
FibroGen : Corporate Presentation – May 2024
PU
Top Premarket Gainers
MT
FibroGen to Participate in Upcoming Investor Conferences
AQ
Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024
FibroGen: Q1 Earnings Snapshot
AQ
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M
MT
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
FibroGen Reports First Quarter 2024 Financial Results
AQ
FibroGen to Report First Quarter 2024 Financial Results
AQ
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.